Compare
Amgen vs Sarepta Therapeutics (AMGN vs SRPT)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Sarepta Therapeutics (SRPT) -4.5%; so far this year the figures are +40.7% and -17.2%.
Amgen is the larger company by market value, about 130.4 times the size of Sarepta Therapeutics.
Revenue grew +8.2% at AMGN and -36.6% at SRPT over the last year.
AMGN yields 2.16%. SRPT pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | SRPT | |
|---|---|---|
| Price | $460.42 | $17.82 |
| 1-day | +0.03% | +1.42% |
| YTD | +40.67% | -17.19% |
| 1 year | +43.94% | -4.55% |
| 3 years | +76.51% | -76.71% |
| Market cap | $249.1B | $1.9B |
| P/E | 26.7 | — |
| P/S | 6.40 | 1.41 |
| P/B | 17.35 | 1.25 |
| Revenue growth | +8.20% | -36.60% |
| EPS growth | +33.30% | — |
| Gross margin % | 70.9 | 135.9 |
| Net margin % | 24.1 | -8.5 |
| ROE % | 65.4 | -7.5 |
| Debt / equity | 3.76 | 0.66 |
| FCF yield % | 3.8 | 9.2 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 1.78 |
| RSI (14) | 60.5 | 46.1 |
| Technical rating |